CD抗原癌症治療市場按治療方法和癌症類型分類 - 全球預測（2025-2032年）

預計到 2032 年，CD 抗原癌症治療市場將成長至 182.2 億美元，複合年成長率為 6.40%。

CD抗原標靶腫瘤治療方法的權威概述，整合了科學證據、臨床進展和商業影響，以供決策者參考。

標靶CD抗原的癌症治療是一個融合了分子生物學、免疫工程和精準遞送技術的交叉領域，旨在產生新的治療方法。過去十年，轉化研究不斷發現一系列CD表面標誌物，這些標記可用於選擇性地區分惡性組織和正常組織，從而設計出既能有效治療又能控制毒性的抗體偶聯物、基因修飾細胞療法和最佳化生物製藥。

多種CD標靶在骨髓惡性腫瘤的臨床療效激發了人們將其應用拓展至固態腫瘤固態腫瘤的興趣。實體腫瘤中腫瘤微環境的異質性和抗原表現的變異性增加了治療的複雜性。同時，生產技術的進步和監管政策的調整正在縮短複雜生物製藥的研發週期，並增加進入後期研發階段的候選藥物數量。這些變化擴大了相關人員的範圍，不僅包括專業的生物技術公司，還包括成熟的製藥公司、契約製造組織和專業服務供應商。

綜上所述，這些趨勢表明，針對CD抗原的治療方法已成為致力於尋求永續靶向腫瘤解決方案的機構的策略重點。因此，將科學潛力轉化為永續的臨床和商業性影響，需要認真考慮轉化科學、臨床試驗設計、供應鏈韌性以及與支付者的合作。

工程、監管和製造領域的融合創新將如何重新定義靶向CD抗原的癌症治療性介入的發展軌跡和商業性動態

由於技術和製度因素的共同作用，CD抗原癌症治療領域正經歷著變革性的轉變。標靶有效載荷工程和連接子化學的進步提高了抗體藥物複合體的治療指數，從而增強了腫瘤選擇性並降低了脫靶效應。同時，整合了邏輯門控、強化細胞激素表現和關閉機制的新一代CAR-T細胞構建體，將細胞療法的應用範圍從血液系統惡性腫瘤擴展到某些固態腫瘤。

隨著科學的進步，法規結構也在不斷發展，以適應生物製藥的複雜性。監管機構越來越重視適應性研究設計和真實世界數據，以此核准途徑。分散式生產模式、自動化和數位化批次追蹤等製造創新正在重新定義可擴展性和品管實踐，從而降低高度複雜療法的營運阻力。在商業方面，相關人員的期望正轉向整合診斷、可近性支援和長期病患監測的醫療解決方案。

因此，那些將研發重點與靈活製造、可靠的證據產生和協作支付策略相結合的組織，將最有能力抓住機遇，在一個獎勵技術差異化和以患者為中心的服務模式的環境中。

評估關稅政策的變化如何重塑CD抗原癌症治療價值鏈的採購、製造地和業務永續營運韌性。

預計2025年美國生效的關稅政策累積將對CD抗原癌症療法的採購、生產和臨床供應鏈產生連鎖反應。進口試劑、一次性塑膠製品、特殊過濾膜和某些實驗室設備的關稅可能會逐步增加生物製藥生產和臨床試驗所需關鍵材料的到岸成本。因此，早期研發專案的營運利潤率可能會受到壓縮，並且檢測樣本處理和生物製程耗材的可變成本也會增加。

此外，關稅帶來的成本壓力可能會影響策略採購決策，促使企業增加供應鏈在地化力度，並重新投資於國內製造能力。雖然這種轉變將在長期內提高供應可靠性，但通常需要領先資本投入和人才培養，以加強無菌保證、無菌填充和包裝以及低溫運輸物流的能力。同時，缺乏一體化製造能力的小型開發商和學術贊助商可能會面臨更大的營運挑戰，從而凸顯契約製造夥伴關係和聯合採購模式的重要性。

簡言之，關稅政策的發展將成為結構性變量，可能重塑供應商選擇、製造地和成本管理策略。因此，積極主動的情境規劃和策略性的供應商合作至關重要，既能減輕短期衝擊，又能從更具韌性、地域分散的生產生態系統中獲得長期效益。

基於細分市場的關鍵洞察表明，治療方法方式和癌症適應症如何共同決定研發的複雜性、監管方法和商業化路徑。

細分市場分析揭示了不同治療方法和疾病適應症在研發路徑和策略重點上的顯著差異，這影響著臨床設計、生產複雜性和商業化策略。根據治療方法類型，市場可分為抗體藥物複合體(ADC)、嵌合體抗原受體 (CAR) T 細胞療法和單株抗體，涵蓋了從標靶有效載荷遞送到活細胞療法再到經典生物學機制的連續光譜。每種治療方法都有其獨特的需求：抗體藥物複合體需要先進的連接子和有效載荷最佳化，以及可靠的腫瘤穿透評估；CAR T 細胞療法需要個性化的細胞採集、體外操作和長期安全性監測；而單克隆抗體則依賴成熟的生物製藥生產過程和大規模配銷通路。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

• 開發具有增強細胞激素分泌機制的下一代CD19 CAR-T療法，以提高療效持久性並降低復發率
• 雙抗原標靶雙特異性抗體的進展提高了三陰性乳癌治療的特異性
• 將CD22定向CAR-T療法與查核點抑制劑聯合治療結合，以克服腫瘤微環境抑制
• 新興的基於RNA的CD抗原疫苗平台可誘導針對兒童白血病新抗原的免疫反應
• CD70標靶抗體藥物複合體的臨床進展表明，其在腎細胞癌患者中具有更佳的安全性。
• 投資趨勢推動了基於奈米抗體的CD抗原療法實現腫瘤深層滲透和低免疫抗原性。
• 自體CD33靶向CAR-NK細胞療法在急性骨髓性白血病治療管線中加速獲得監管部門核准。
• 利用液態生物檢體檢測監測CD抗原表達動態，以指導個人化免疫治療劑量策略

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. CD抗原癌症治療市場（依治療方法）

• 抗體藥物複合體
• 嵌合體抗原受體（CAR）T細胞療法
• 單株抗體

第9章 CD抗原癌症治療市場（按癌症類型分類）

• 骨髓惡性腫瘤
• 固態腫瘤

第10章 CD抗原癌症治療市場（按地區分類）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第11章 CD抗原癌症治療市場（依組別分類）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第12章 CD抗原癌症治療市場（按國家/地區分類）

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第13章 競爭格局

• 2024年市佔率分析
• FPNV定位矩陣，2024
• 競爭分析
  • Roche Holding AG
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Janssen Biotech, Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Seagen Inc.
  • Allogene Therapeutics, Inc.
  • Cellectis SA

The CD Antigen Cancer Therapy Market is projected to grow by USD 18.22 billion at a CAGR of 6.40% by 2032.

An authoritative overview of CD antigen-directed oncology approaches that synthesizes scientific rationale, clinical momentum, and commercialization implications for decision-makers

CD antigen-targeted cancer therapies represent a convergent space where molecular biology, immune engineering, and precision delivery technologies intersect to create new modalities of care. Over the past decade, translational research has progressively clarified which cluster of CD surface markers can be selectively exploited to distinguish malignant from healthy tissue, enabling the design of antibody-based conjugates, engineered cellular therapies, and optimized biologics that deliver efficacy while managing toxicity.

Clinical validation of multiple CD targets in hematological malignancies has catalyzed interest in expanding those approaches into solid tumors, where tumor microenvironment heterogeneity and antigen expression variability create additional complexities. Concurrently, manufacturing advances and regulatory adaptations have reduced development timelines for complex biologics, increasing the number of assets advancing into late-stage development. These shifts have broadened the stakeholder base to include not only specialized biotech innovators but also established pharmaceutical companies, contract manufacturing organizations, and specialized service providers.

Taken together, these dynamics position CD antigen-targeted approaches as a strategic priority for organizations pursuing durable, targeted oncology solutions. As a result, careful attention to translational science, clinical design, supply chain resilience, and payer engagement will be required to convert scientific promise into sustainable clinical and commercial impact.

How convergent innovations in engineering, regulation, and manufacturing are redefining the trajectory and commercial dynamics of CD antigen-targeted oncology interventions

The landscape for CD antigen cancer therapies is undergoing transformative shifts driven by convergent technological and systemic forces. Advances in targeted payload engineering and linker chemistry have enhanced the therapeutic index of antibody-drug conjugates, enabling higher tumor selectivity and reduced off-target effects. At the same time, next-generation CAR T-cell constructs that incorporate logic gating, armored cytokine expression, and off-switch mechanisms are extending the feasibility of cellular therapies beyond blood cancers and into certain solid tumor niches.

Parallel to scientific progress, regulatory frameworks are evolving to accommodate complex biologics, with agencies increasingly receptive to adaptive trial designs and real-world evidence to inform approval pathways. Manufacturing innovations such as decentralized production models, automation, and digital batch tracking are redefining scalability and quality control practices, thereby lowering operational friction for high-complexity therapies. In commercial terms, stakeholder expectations are shifting toward integrated care solutions that bundle diagnostics, access support, and long-term patient monitoring.

Consequently, organizations that align R&D priorities with flexible manufacturing, robust evidence generation, and collaborative payer strategies will be best positioned to capture opportunity in a landscape that rewards technical differentiation and patient-centered delivery models.

Assessing how tariff policy changes are reshaping sourcing, manufacturing footprints, and operational resilience across the CD antigen oncology value chain

The cumulative impact of tariff policy shifts in the United States in 2025 is expected to reverberate across procurement, manufacturing, and clinical supply networks involved in CD antigen cancer therapies. Tariffs on imported reagents, single-use plastics, specialized filtration membranes, and certain laboratory instruments can incrementally raise the landed cost of critical inputs required for biologics production and clinical trial execution. As a consequence, organizations may experience compressed operating margins on early-stage programs and face higher variable costs for trial sample handling and bioprocessing consumables.

Moreover, tariff-driven cost pressures can influence strategic sourcing decisions, prompting greater localization of supply chains and renewed investment in domestic manufacturing capacity. This pivot may improve supply reliability over time but often requires upfront capital expenditures and workforce development to shore up capabilities in sterility assurance, aseptic fill-finish, and cold chain logistics. In parallel, smaller developers and academic sponsors that lack integrated manufacturing may face amplified operational challenges, increasing the importance of contract manufacturing partnerships and collaborative procurement models.

In sum, tariff dynamics function as a structural variable that can reshape vendor selection, manufacturing footprints, and cost management strategies. Proactive scenario planning and strategic supplier engagement are therefore essential to mitigate short-term disruptions while capturing the long-term benefits of a more resilient and geographically diversified production ecosystem.

Critical segmentation-driven insights demonstrating how therapy modality and cancer indication jointly dictate development complexity, regulatory approach, and commercialization pathways

Segmentation analysis reveals meaningful differences in development pathways and strategic focus across modality and disease indications, with implications for clinical design, manufacturing complexity, and commercialization approaches. Based on Therapy Type, market is studied across Antibody-Drug Conjugates, Chimeric Antigen Receptor (CAR) T-cell Therapy, and Monoclonal Antibodies, which collectively span a continuum from targeted payload delivery to living cell modalities and classic biologic mechanisms. Each therapy type presents distinct requirements: antibody-drug conjugates necessitate advanced linker and payload optimization and robust tumor penetration assessments; CAR T-cell programs demand individualized cell collection, ex vivo manipulation, and long-term safety monitoring; monoclonal antibodies rely on well-established biologics manufacturing and large-scale distribution channels.

Based on Cancer Type, market is studied across Hematological Malignancies and Solid Tumors, categories that diverge in antigen accessibility, microenvironmental hurdles, and clinical endpoint expectations. Hematological malignancies often provide more uniform antigen expression and established response criteria, enabling faster proof-of-concept studies, whereas solid tumors require strategies to address antigen heterogeneity, stromal barriers, and intratumoral delivery. Together, these intersecting segmentation dimensions inform priorities for target selection, trial site networks, companion diagnostic needs, and post-market surveillance strategies. Accordingly, sponsors should tailor development plans to the modality-specific manufacturing pathways and the clinical complexities associated with the targeted cancer type.

How regional regulatory regimes, clinical ecosystems, and manufacturing footprints shape differentiated development and market entry strategies across global regions

Regional dynamics materially influence development, access, and adoption trajectories for CD antigen therapies, with differentiated regulatory environments, clinical trial ecosystems, and payer considerations across major geographies. In the Americas, sizable clinical trial capacity, centralized regulatory review structures, and a high concentration of specialized treatment centers accelerate first-in-human studies and commercial launches, while also necessitating robust evidence packages that address payer scrutiny. Europe, Middle East & Africa present a heterogeneous landscape where centralized and national regulatory requirements coexist, reimbursement pathways vary significantly by market, and regional manufacturing hubs can play a strategic role in addressing supply continuity and market access timelines. Asia-Pacific features rapidly expanding research capacity, growing domestic biotech ecosystems, and evolving regulatory frameworks that increasingly support expedited reviews and localized manufacturing partnerships, making the region both a production and patient recruitment priority for many sponsors.

These regional characteristics affect strategic choices about trial site selection, regulatory filings, and commercial deployment. Sponsors should consider leveraging regional centers of excellence for complex therapy delivery, aligning evidence generation with diverse payer expectations, and planning manufacturing footprints that reduce logistical risk while optimizing time to patient.

Strategic company-level patterns that reveal how partnerships, platform depth, and manufacturing scale determine competitive positioning in CD antigen oncology

Competitive dynamics among leading companies in the CD antigen therapy arena reflect a mix of platform specialization, strategic collaborations, and manufacturing capability development. Established pharmaceutical companies are increasingly partnering with or acquiring specialized innovators to access cutting-edge payloads, cell engineering platforms, and diagnostic complements. These collaborations often include shared investments in manufacturing scale-up, co-development agreements to expand indications, and licensing models that balance risk with potential upside.

Smaller biotechs and cell therapy pioneers continue to drive scientific differentiation through novel antigen targeting, multi-specific constructs, and improved safety switches for cellular products. At the same time, specialized contract service providers and manufacturing partners have expanded capacity and expertise to support complex biologics and autologous therapy workflows, offering modular solutions that allow sponsors to accelerate timelines without fully internalizing capital-intensive production. Overall, successful organizations demonstrate a blend of technological depth, robust clinical development strategies, and an operational focus on quality systems, regulatory readiness, and supply chain resilience that together enable sustained advancement from R&D through commercialization.

Actionable strategic directives that align scientific validation, manufacturing agility, and evidence generation to unlock durable commercial value from CD antigen therapies

Industry leaders should adopt an integrated strategy that aligns scientific prioritization with operational and commercial execution to maximize the potential of CD antigen-targeted therapies. First, prioritize target validation and patient selection strategies early in development to de-risk expensive late-stage studies and to strengthen the value proposition for payers and partners. Second, invest in manufacturing flexibility by combining internal capabilities with validated contract manufacturing partners to balance scale, speed, and quality assurance while hedging against supply chain disruptions.

Third, design evidence-generation plans that incorporate prospective real-world data collection and adaptive trial elements to support regulatory dialogue and payer negotiations. Fourth, pursue strategic partnerships that couple complementary platforms-such as combining antibody-drug conjugate expertise with novel payload chemistry or pairing cell therapy engineering with scalable manufacturing platforms-to accelerate time to proof-of-concept. Finally, build multidisciplinary commercialization playbooks that include diagnostic alignment, long-term safety monitoring plans, and patient support services to facilitate adoption and reimbursement. By executing on these pragmatic, coordinated actions, companies can convert technological promise into durable clinical and commercial outcomes.

A transparent and reproducible mixed-methods approach combining expert interviews, literature synthesis, and iterative validation to underpin rigorous market insights

The research methodology underpinning this analysis integrates primary and secondary approaches to ensure rigor, triangulation, and relevance to decision-makers. Primary research included structured interviews with industry executives, clinical investigators, manufacturing experts, and payers to capture real-world perspectives on development bottlenecks, operational constraints, and commercial priorities. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map technological trends, clinical progress, and regulatory precedent.

Data synthesis employed cross-validation techniques and expert panels to reconcile divergent views and to test scenario assumptions. The methodology emphasized transparency in source attribution, iterative expert review cycles, and sensitivity checks to highlight areas of consensus and uncertainty. Limitations include rapidly evolving clinical data streams and region-specific regulatory changes that may alter the competitive landscape; consequently, the analysis is designed to be operationalized through periodic updates, targeted follow-up interviews, and tailored workshops that extend the core findings into bespoke strategic plans.

A synthesis that distills the scientific promise and operational realities of CD antigen therapies into strategic priorities for translating innovation into accessible oncology care

In conclusion, CD antigen-targeted cancer therapies occupy a strategic frontier of oncology innovation where scientific advances, manufacturing evolution, and regulatory adaptation converge to create meaningful clinical opportunities. The interplay between modality-specific complexities and indication-driven clinical challenges underscores the need for tailored development strategies that balance technical differentiation with pragmatic operational planning. Moreover, external factors such as trade policy and regional regulatory divergence introduce structural considerations that can influence sourcing, manufacturing localization, and evidence strategies.

Organizations that integrate robust target validation, flexible manufacturing partnerships, and proactive payer-engagement plans will be well-positioned to navigate the emerging landscape. Ultimately, success in this domain requires a systems-level perspective that aligns translational science, clinical design, and commercial execution to deliver therapies that are not only effective but also accessible and sustainable for patients and health systems alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Development of next generation CD19 CAR T therapies with armored cytokine secretion for improved durability and reduced relapse rates
• 5.2. Advancements in dual antigen targeting bispecific antibodies for enhanced specificity in treating triple negative breast cancer
• 5.3. Integration of CD22-directed CAR T therapy with checkpoint inhibitor combination regimens to overcome tumor microenvironment suppression
• 5.4. Emergence of RNA-based CD antigen vaccine platforms to prime immune response against neoantigens in pediatric leukemias
• 5.5. Clinical progress of CD70-targeted antibody drug conjugates demonstrating improved safety profiles in renal cell carcinoma patients
• 5.6. Investment trends driven by nanobody-based CD antigen therapies enabling deeper tumor penetration and lower immunogenicity
• 5.7. Regulatory approvals accelerating for autologous CD33-targeted CAR NK cell therapies in acute myeloid leukemia treatment pipelines
• 5.8. Adoption of liquid biopsy assays for monitoring CD antigen expression dynamics to guide personalized immunotherapy dosing strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CD Antigen Cancer Therapy Market, by Therapy Type

• 8.1. Antibody-Drug Conjugates
• 8.2. Chimeric Antigen Receptor (CAR) T-cell Therapy
• 8.3. Monoclonal Antibodies

9. CD Antigen Cancer Therapy Market, by Cancer Type

• 9.1. Hematological Malignancies
• 9.2. Solid Tumors

10. CD Antigen Cancer Therapy Market, by Region

• 10.1. Americas
  • 10.1.1. North America
  • 10.1.2. Latin America
• 10.2. Europe, Middle East & Africa
  • 10.2.1. Europe
  • 10.2.2. Middle East
  • 10.2.3. Africa
• 10.3. Asia-Pacific

11. CD Antigen Cancer Therapy Market, by Group

• 11.1. ASEAN
• 11.2. GCC
• 11.3. European Union
• 11.4. BRICS
• 11.5. G7
• 11.6. NATO

12. CD Antigen Cancer Therapy Market, by Country

• 12.1. United States
• 12.2. Canada
• 12.3. Mexico
• 12.4. Brazil
• 12.5. United Kingdom
• 12.6. Germany
• 12.7. France
• 12.8. Russia
• 12.9. Italy
• 12.10. Spain
• 12.11. China
• 12.12. India
• 12.13. Japan
• 12.14. Australia
• 12.15. South Korea

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Analysis
  • 13.3.1. Roche Holding AG
  • 13.3.2. Novartis AG
  • 13.3.3. Gilead Sciences, Inc.
  • 13.3.4. Bristol-Myers Squibb Company
  • 13.3.5. Janssen Biotech, Inc.
  • 13.3.6. Amgen Inc.
  • 13.3.7. Pfizer Inc.
  • 13.3.8. Seagen Inc.
  • 13.3.9. Allogene Therapeutics, Inc.
  • 13.3.10. Cellectis S.A.

LIST OF FIGURES

• FIGURE 1. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 7. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 9. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. CD ANTIGEN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 24. CD ANTIGEN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CD ANTIGEN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 42. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 43. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 44. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 45. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 46. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 47. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 48. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 49. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 50. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 51. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 52. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 53. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 56. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 57. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 58. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 62. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 63. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 64. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 65. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 68. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 69. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 70. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 71. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 74. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 75. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 76. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 77. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 80. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 81. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 82. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 83. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 86. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 87. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 88. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 94. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 95. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 96. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 97. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 100. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 101. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 102. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 103. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 106. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 107. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 108. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 109. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 112. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 113. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 114. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 115. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 118. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 119. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 120. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 121. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 124. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 125. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 126. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 130. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 131. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 132. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 133. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 134. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 135. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 136. CANADA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 137. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 138. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 139. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 140. MEXICO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 141. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 142. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 143. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 144. BRAZIL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 145. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 146. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 147. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 148. UNITED KINGDOM CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 149. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 150. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 151. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 152. GERMANY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 153. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 154. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 155. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 156. FRANCE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 157. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 158. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 159. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 160. RUSSIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 161. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 162. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 163. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 164. ITALY CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 165. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 166. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 167. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 168. SPAIN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 169. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 170. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 171. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 172. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 173. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 174. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 175. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 176. INDIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 177. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 178. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 179. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 180. JAPAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 181. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 182. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 183. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 184. AUSTRALIA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 185. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
• TABLE 186. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
• TABLE 187. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
• TABLE 188. SOUTH KOREA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
• TABLE 189. CD ANTIGEN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 190. CD ANTIGEN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2024